Liver Failure - Pipeline Review, H2 2015

Date: October 30, 2015
Pages: 72
Price:
US$ 2,000.00 US$ 1,600.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: L33855AFB4AEN
Leaflet:

Download PDF Leaflet

Liver Failure - Pipeline Review, H2 2015

SUMMARY

Global Markets Direct’s, ‘Liver Failure - Pipeline Review, H2 2015’, provides an overview of the Liver Failure’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Liver Failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver Failure and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Liver Failure
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Liver Failure and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Liver Failure products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Liver Failure pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
REASONS TO BUY
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Liver Failure
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Liver Failure pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Liver Failure Overview
Therapeutics Development
Pipeline Products for Liver Failure - Overview
Pipeline Products for Liver Failure - Comparative Analysis
Liver Failure - Therapeutics under Development by Companies
Liver Failure - Therapeutics under Investigation by Universities/Institutes
Liver Failure - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Liver Failure - Products under Development by Companies
Liver Failure - Products under Investigation by Universities/Institutes
Liver Failure - Companies Involved in Therapeutics Development
Alfact Innovation
Cell2B S.A.
Conatus Pharmaceuticals Inc.
Digna Biotech, S.L.
Immune Pharmaceuticals Inc.
Silence Therapeutics Plc
Ventria Bioscience
Liver Failure - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ALF-5755 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cardiotrophin-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell Therapy for Liver Failure - Drug Profile
Product Description
Mechanism of Action
R&D Progress
emricasan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
F-573 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GRI-0621 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hep-114 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ImmuneSafe - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Oligonucleotide for Liver Failure - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Protein to Inhibit JNK for Liver Failure - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RNAi Oligonucleotide for Liver Diseases - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RNAi Oligonucleotides to Inhibit MAP Kinase 4 for Liver Failure - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Activate Glutathione Peroxidase for Ischemic Stroke and Liver Failure - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit JNK for Type 2 Diabetes and Liver Failure - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stem Cell Therapy for Osteoarthritis, Diabetes Mellitus, Acute Liver Failure, Post Cardiopulmonary Resuscitation and Neurodegenerative Diseases - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VEN-100 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Liver Failure - Recent Pipeline Updates
Liver Failure - Dormant Projects
Liver Failure - Discontinued Products
Liver Failure - Product Development Milestones
Featured News & Press Releases
Jan 08, 2015: Conatus Announces Top-Line Results From ACLF and Organ Impairment Clinical Trials of Emricasan
Jan 05, 2015: Conatus to Report Top-line Results From ACLF and Organ Impairment Clinical Trials of Emricasan
Nov 02, 2013: Conatus Pharmaceuticals Presents Data Demonstrating Emricasan's Safety Profile at the AASLD Liver Meeting
Apr 02, 2013: ALF-5755 phase II completion
Aug 03, 2012: MDC Researchers Develop New Approach to Treat Acute Liver Failure
Sep 21, 2011: Digna Biotech Receives FDA Orphan Drug Status For Cardiotrophin-1 For Acute Liver Failure Treatment
May 06, 2011: ALF-5755 phase II extends to germany
May 05, 2011: Alfact Innovation Receives Orphan Drug Designation For ALF-5755 From FDA
Mar 16, 2011: Digna Biotech And Biotecnol Receive Spanish Approval For Phase I Clinical Studies Of Cardiotrophin I
Mar 10, 2011: Digna Biotech And Biotecnol Announce Spanish Approval For Phase I Clinical study Of Cardiotrophin I
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Liver Failure, H2 2015
Number of Products under Development for Liver Failure - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
Liver Failure - Pipeline by Alfact Innovation, H2 2015
Liver Failure - Pipeline by Cell2B S.A., H2 2015
Liver Failure - Pipeline by Conatus Pharmaceuticals Inc., H2 2015
Liver Failure - Pipeline by Digna Biotech, S.L., H2 2015
Liver Failure - Pipeline by Immune Pharmaceuticals Inc., H2 2015
Liver Failure - Pipeline by Silence Therapeutics Plc, H2 2015
Liver Failure - Pipeline by Ventria Bioscience, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Liver Failure Therapeutics - Recent Pipeline Updates, H2 2015
Liver Failure - Dormant Projects, H2 2015
Liver Failure - Discontinued Products, H2 2015

LIST OF FIGURES

Number of Products under Development for Liver Failure, H2 2015
Number of Products under Development for Liver Failure - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

COMPANIES MENTIONED

Alfact Innovation
Cell2B S.A.
Conatus Pharmaceuticals Inc.
Digna Biotech, S.L.
Immune Pharmaceuticals Inc.
Silence Therapeutics Plc
Ventria Bioscience
Skip to top


Liver Transplantation - Pipeline Review, H2 2015 US$ 1,700.00 Nov, 2015 · 64 pages
Hepatic (Liver) Metastasis - Pipeline Review, H1 2015 US$ 1,600.00 Apr, 2015 · 61 pages
Liver Cirrhosis - Pipeline Review, H1 2016 US$ 1,700.00 Mar, 2016 · 102 pages
Liver Failure - Pipeline Insights, 2016 US$ 1,000.00 Nov, 2016 · 60 pages
Liver Cancer - Pipeline Review, 2015 US$ 3,200.00 Oct, 2015 · 76 pages

Ask Your Question

Liver Failure - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: